BACKGROUND: Patients scheduled to receive chemotherapy frequently undergo pretherapy dental treatment to eliminate potential sources of odontogenic infection. A prospective study was conducted to assess a new protocol emphasizing minimal pretherapy dental treatment. METHODS: Forty-eight consecutive patients diagnosed with solid or hematologic neoplasms underwent dental examination prior to intensive chemotherapy. All chronic dental pathology was scored as either mild-to-moderate or severe based on the likelihood of conversion to an acute state during chemotherapy. No pretherapy dental treatment was given to patients with chronic dental disease. Intertherapy dental complications and the overall impact on chemotherapy outcomes were assessed. RESULTS: Thirty-eight patients (79%) were diagnosed with pretherapy chronic dental pathology. Twenty-one of these patients (44% of the total population) were identified as having severe pathology and considered at risk for acute intertherapy dental complications. Two patients (4%) experienced acute intertherapy episodes, each presenting as oral abscesses. In both cases, resolution was achieved with antibiotics without interruption of chemotherapy. Oncologic treatment outcomes for all patients were judged to be unaffected by either the presence of chronic pretherapy dental disease or acute intertherapy exacerbations of these disease states. CONCLUSIONS: These results demonstrate that patients with chronic dental pathology can safely proceed with chemotherapy without dental intervention, as conversion of chronic dental disease to an acute state during chemotherapy occurs infrequently. If intertherapy dental infections do arise, they can be managed effectively without interrupting therapy or adversely affecting oncologic treatment outcomes.
BACKGROUND:Patients scheduled to receive chemotherapy frequently undergo pretherapy dental treatment to eliminate potential sources of odontogenic infection. A prospective study was conducted to assess a new protocol emphasizing minimal pretherapy dental treatment. METHODS: Forty-eight consecutive patients diagnosed with solid or hematologic neoplasms underwent dental examination prior to intensive chemotherapy. All chronic dental pathology was scored as either mild-to-moderate or severe based on the likelihood of conversion to an acute state during chemotherapy. No pretherapy dental treatment was given to patients with chronic dental disease. Intertherapy dental complications and the overall impact on chemotherapy outcomes were assessed. RESULTS: Thirty-eight patients (79%) were diagnosed with pretherapy chronic dental pathology. Twenty-one of these patients (44% of the total population) were identified as having severe pathology and considered at risk for acute intertherapy dental complications. Two patients (4%) experienced acute intertherapy episodes, each presenting as oral abscesses. In both cases, resolution was achieved with antibiotics without interruption of chemotherapy. Oncologic treatment outcomes for all patients were judged to be unaffected by either the presence of chronic pretherapy dental disease or acute intertherapy exacerbations of these disease states. CONCLUSIONS: These results demonstrate that patients with chronic dental pathology can safely proceed with chemotherapy without dental intervention, as conversion of chronic dental disease to an acute state during chemotherapy occurs infrequently. If intertherapy dental infections do arise, they can be managed effectively without interrupting therapy or adversely affecting oncologic treatment outcomes.
Authors: Catherine H L Hong; Shijia Hu; Thijs Haverman; Monique Stokman; Joel J Napeñas; Jacolien Bos-den Braber; Erich Gerber; Margot Geuke; Emmanouil Vardas; Tuomas Waltimo; Siri Beier Jensen; Deborah P Saunders Journal: Support Care Cancer Date: 2017-07-22 Impact factor: 3.603
Authors: K Tsuji; Y Shibuya; M Akashi; S Furudoi; K Yakushijin; S Kawamoto; A Okamura; H Matsuoka; T Komori Journal: J Dent Res Date: 2014-12-10 Impact factor: 6.116
Authors: Catherine H L Hong; Joel J Napeñas; Brian D Hodgson; Monique A Stokman; Vickie Mathers-Stauffer; Linda S Elting; Fred K L Spijkervet; Michael T Brennan Journal: Support Care Cancer Date: 2010-05-07 Impact factor: 3.603
Authors: Heidi J Hansen; Cherry Estilo; Adepitan Owosho; Armand Karl Solano; Joseph Randazzo; Joseph Huryn; SaeHee K Yom Journal: Support Care Cancer Date: 2020-09-08 Impact factor: 3.603
Authors: J M Schuurhuis; L F R Span; M A Stokman; A J van Winkelhoff; A Vissink; F K L Spijkervet Journal: Br J Cancer Date: 2016-03-22 Impact factor: 7.640